Vlada Gurvich38 min listen
GRIP2 min read
Vlada Gurvich46 min listen
Hameed Shuja3 min read
Vlada Gurvich38 min listen
Julie DiMauro2 min read

Vlada Gurvich explores these intricate topics with the DC- and Atlanta-based experts.
Vlada Gurvich38 min listen

Principal third-party disclosure mechanisms and the common pitfalls for pharmaceutical compliance and risk teams.

The new bill would have government agencies referring to the Department of Defense’s 1260H list of Chinese military companies operating in the US.
Kevin Kinsella2 min read

Canada’s 2025 budget ties hundreds of billions in capital spending to housing, infrastructure, and critical minerals in a calculated gamble that industrial policy can deliver both resilience and growth.
Vlada Gurvich5 min read

The ups and downs of the proposed deal demonstrate the evolving landscape of compliance in the context of geopolitical tensions.
Kevin Kinsella2 min read

The report urges Congress to bolster US pharmaceutical supply-chain resilience and reduce dependence on China.
Kevin Kinsella2 min read

Significant developments in the healthcare sector are pulling at the integrity of the entire system.
Vlada Gurvich3 min read

In a word where global supply chains define who benefits from progress, Power and Progress offers not just a warning, but a call “for reimagining a better future.”
Vlada Gurvich, Alexander Barzacanos9 min read